These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

904 related articles for article (PubMed ID: 31057295)

  • 21. OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ.
    Zhang Z; Du J; Wang S; Shao L; Jin K; Li F; Wei B; Ding W; Fu P; van Dam H; Wang A; Jin J; Ding C; Yang B; Zheng M; Feng XH; Guan KL; Zhang L
    Mol Cell; 2019 Jan; 73(1):7-21.e7. PubMed ID: 30472188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
    Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
    J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. YAP/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC.
    Choi W; Kim J; Park J; Lee DH; Hwang D; Kim JH; Ashktorab H; Smoot D; Kim SY; Choi C; Koh GY; Lim DS
    Cancer Res; 2018 Jun; 78(12):3306-3320. PubMed ID: 29669762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.
    Mueller S; Engleitner T; Maresch R; Zukowska M; Lange S; Kaltenbacher T; Konukiewitz B; Öllinger R; Zwiebel M; Strong A; Yen HY; Banerjee R; Louzada S; Fu B; Seidler B; Götzfried J; Schuck K; Hassan Z; Arbeiter A; Schönhuber N; Klein S; Veltkamp C; Friedrich M; Rad L; Barenboim M; Ziegenhain C; Hess J; Dovey OM; Eser S; Parekh S; Constantino-Casas F; de la Rosa J; Sierra MI; Fraga M; Mayerle J; Klöppel G; Cadiñanos J; Liu P; Vassiliou G; Weichert W; Steiger K; Enard W; Schmid RM; Yang F; Unger K; Schneider G; Varela I; Bradley A; Saur D; Rad R
    Nature; 2018 Feb; 554(7690):62-68. PubMed ID: 29364867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model.
    Chang HH; Moro A; Chou CEN; Dawson DW; French S; Schmidt AI; Sinnett-Smith J; Hao F; Hines OJ; Eibl G; Rozengurt E
    Sci Rep; 2018 Apr; 8(1):5899. PubMed ID: 29651002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
    Lamar JM; Xiao Y; Norton E; Jiang ZG; Gerhard GM; Kooner S; Warren JSA; Hynes RO
    J Biol Chem; 2019 Feb; 294(7):2302-2317. PubMed ID: 30559289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoxic conditions differentially regulate TAZ and YAP in cancer cells.
    Yan L; Cai Q; Xu Y
    Arch Biochem Biophys; 2014 Nov; 562():31-6. PubMed ID: 25078107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
    Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
    J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis.
    Wang KC; Yeh YT; Nguyen P; Limqueco E; Lopez J; Thorossian S; Guan KL; Li YJ; Chien S
    Proc Natl Acad Sci U S A; 2016 Oct; 113(41):11525-11530. PubMed ID: 27671657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of curcumin is involved in down-regulation of YAP/TAZ expression in pancreatic cancer cells.
    Zhou X; Su J; Feng S; Wang L; Yin X; Yan J; Wang Z
    Oncotarget; 2016 Nov; 7(48):79076-79088. PubMed ID: 27738325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Hippo Signaling Pathway in Pancreatic Cancer.
    Ansari D; Ohlsson H; Althini C; Bauden M; Zhou Q; Hu D; Andersson R
    Anticancer Res; 2019 Jul; 39(7):3317-3321. PubMed ID: 31262852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
    Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
    Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of YAP, TAZ and HSP90 in contact guidance and intercellular junction formation in corneal epithelial cells.
    Raghunathan VK; Dreier B; Morgan JT; Tuyen BC; Rose BW; Reilly CM; Russell P; Murphy CJ
    PLoS One; 2014; 9(10):e109811. PubMed ID: 25290150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy.
    Pobbati AV; Hong W
    Theranostics; 2020; 10(8):3622-3635. PubMed ID: 32206112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet‑derived growth factor‑BB mediates pancreatic cancer malignancy via regulation of the Hippo/Yes‑associated protein signaling pathway.
    Li T; Guo T; Liu H; Jiang H; Wang Y
    Oncol Rep; 2021 Jan; 45(1):83-94. PubMed ID: 33416116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
    Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
    Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin Receptor and GPCR Crosstalk Stimulates YAP via PI3K and PKD in Pancreatic Cancer Cells.
    Hao F; Xu Q; Zhao Y; Stevens JV; Young SH; Sinnett-Smith J; Rozengurt E
    Mol Cancer Res; 2017 Jul; 15(7):929-941. PubMed ID: 28360038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting cell surface GRP78 enhances pancreatic cancer radiosensitivity through YAP/TAZ protein signaling.
    Gopal U; Mowery Y; Young K; Pizzo SV
    J Biol Chem; 2019 Sep; 294(38):13939-13952. PubMed ID: 31358620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications.
    Maugeri-Saccà M; Barba M; Pizzuti L; Vici P; Di Lauro L; Dattilo R; Vitale I; Bartucci M; Mottolese M; De Maria R
    Expert Rev Mol Med; 2015 Jul; 17():e14. PubMed ID: 26136233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
    Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
    Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.